Axsome Therapeutics Inc is primarily active in the pharmaceutical industry.

The main competitors of Axsome Therapeutics Inc in the market include pharmaceutical companies such as Sage Therapeutics, Zosano Pharma Corporation, and Marinus Pharmaceuticals. Axsome Therapeutics Inc develops innovative treatments for central nervous system (CNS) disorders, focusing on difficult-to-treat conditions. With its unique product pipeline and research-driven approach, Axsome competes with these companies in developing novel therapeutics for CNS disorders.

Axsome Therapeutics Inc is a renowned biopharmaceutical company with a rich history and background. Founded in 2012, Axsome is dedicated to developing innovative therapies to improve the lives of patients suffering from central nervous system (CNS) disorders. The company focuses on areas such as depression, Alzheimer's disease, migraines, and other related conditions. Axsome Therapeutics Inc has a diverse pipeline of potential treatments and utilizes cutting-edge research and clinical trials to drive their drug development process. With a steadfast commitment to improving patient outcomes, Axsome Therapeutics Inc is emerging as a key player in the field of CNS therapeutics.

Axsome Therapeutics Inc has achieved several significant milestones. The company successfully received FDA approval for its product, which has shown promising results in clinical trials. Additionally, Axsome Therapeutics Inc has established strategic partnerships with key industry players and has expanded its product pipeline to target various medical conditions. Moreover, the company has successfully raised funding from renowned investors, enabling it to further advance its research and development efforts. Axsome Therapeutics Inc continues to make significant progress in the field of therapeutic treatments and is dedicated to improving the lives of patients.

Axsome Therapeutics Inc is primarily present in the United States.

Axsome Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's core values revolve around advancing the treatment options for patients suffering from CNS conditions such as major depressive disorder, Alzheimer's disease, and narcolepsy. Axsome Therapeutics Inc is committed to rigorous research and development to deliver breakthrough medicines that improve patients' lives. With a strong corporate philosophy centered on scientific excellence, patient-centricity, and a dedication to healthcare innovation, Axsome Therapeutics Inc aims to address unmet medical needs and make a lasting impact in the field of CNS disorders.

Analysts currently set an average price target of 217,31 USD for the Axsome Therapeutics stock (median: 218,28 USD), implying +1,7 % versus the latest price. The consensus is based on 26 analyst ratings.

Axsome Therapeutics Analyytikkojen kursstavoitteet 2026

26 analysts currently rate the Axsome Therapeutics stock: 24 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Axsome Therapeutics to generate revenue of 974,07 M USD and earnings per share of −2,48 USD.

Axsome Therapeutics Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Axsome Therapeutics share trades at 186,75 EUR (215,99 USD).

The Axsome Therapeutics share (AXSM) is listed on 6 stock exchanges, including: NASDAQ (AXSM), Frankfurt (19X.F), München (19X.MU), Düsseldorf (19X.DU), London (0HKF.L), London (0HKF.L).

Axsome Therapeutics Inc is a publicly-traded biopharmaceutical company based in New York City that develops effective and safe therapies for patients with severe neurological disorders. The company primarily focuses on developing treatments for patients with depression, schizophrenia, Alzheimer's disease, fibromyalgia, and other serious neurological disorders. Axsome's business model is based on developing innovative therapies for patients that are currently not available on the market or have limited effectiveness. The company utilizes a combination of proprietary technologies and partnerships with leading academic institutions to develop these therapies. Axsome Therapeutics has focused on developing medications tailored to the needs of patients who cannot find appropriate treatment elsewhere. The company has successfully advanced its clinical development programs and demonstrated the potential to introduce new therapies for difficult-to-treat patients. Axsome Therapeutics has several products in clinical trials, including AXS-05, an NMDA receptor antagonist currently being developed for the treatment of depression and Alzheimer's disease. The company also has AXS-07, a new migraine medication, AXS-12 for the treatment of cataplexy in patients with narcolepsy, and AXS-14 for the treatment of fibromyalgia in clinical trials. To operate its business model successfully, Axsome Therapeutics utilizes a wide range of partnerships and distribution channels. The company works closely with academic centers and other industry leaders to evaluate and develop innovative solutions for difficult-to-treat patients. Additionally, Axsome Therapeutics collaborates with a number of strategic partners, including specialized CROs (contract research organizations) and distribution partners, to collect safety and efficacy data for its development programs and develop marketing strategies. Finally, Axsome Therapeutics also leverages the benefits of digital technologies to optimize its business model and improve access to its therapies. The company utilizes modern digital platforms to raise awareness among patients suffering from the diseases they treat about their clinical trials. This way, Axsome Therapeutics can potentially recruit more patients for their clinical trials and bring their therapeutics to market faster. In summary, Axsome Therapeutics Inc is an innovative biopharmaceutical company that focuses on developing therapies for difficult-to-treat diseases. The company utilizes a combination of proprietary technologies, strategic partnerships, and digital marketing to optimize its business model and successfully advance its development programs. With several products in clinical trials and a strong pipeline, Axsome Therapeutics is well-positioned to drive both patient well-being and company growth.

odotettu liikevaihto Axsome Therapeutics on 974,07 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Axsome Therapeutics on −125,39 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Axsome Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −87,21. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Axsome Therapeutics-osakkeen arvostusta.

Axsome Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 11,23. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Axsome Therapeutics-osakkeen arvostuskennuslukuna.

Axsome Therapeutics:n Eulpool-laatuscore on 4/10.

Axsome Therapeutics:n ISIN on US05464T1043. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Axsome Therapeutics:n WKN on A2AA7B. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Axsome Therapeutics:n ticker on AXSM. Tämä pörssinoteeraus käytetään Axsome Therapeutics-osakkeiden kauppaan pörssissä.

Axsome Therapeutics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Axsome Therapeutics kuuluu sektoriin 'Terveydenhuolto'.

Axsome Therapeutics:n osingot jaetaan valuutassa USD.